Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Endocyte Inc.

Apr 2009
Endocyte Inc. of West Lafayette, Ind., has initiated a randomized Phase II clinical study of its EC145 drug in women with platinum-resistant ovarian cancer. In addition to the drug, patients will be treated with the company’s EC20 molecular imaging agent, which enables clinicians to identify tumors that overexpress folate receptors.

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2017 Photonics Media
x Subscribe to BioPhotonics magazine - FREE!